Central Nervous System (CNS) Stimulant Drugs Market

1. Analysis of Central Nervous System (CNS) Stimulant Drugs Market Size by Research Nester Reveals the Market to Grow with a CAGR of ~8% during 2024-2036 and Attain ~USD 20 Billion by 2036 Research Nester assesses the growth and market size of global central nervous system (CNS) stimulant drugs market which is anticipated to be on account of the increasing demand from end-use industries and increasing demand for healthcare sector. New York – January 3, 2024 - Research Nester’s recent market research analysis on “Central Nervous System (CNS) Stimulant Drugs Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global central nervous system (CNS) stimulant drugs market in terms of market segmentation by type, end user, and by region. Request Free Sample Copy of this Report @ https://www.researchnester.com/sample-request-5524 Expanding Application in Adult Population to Promote Global Market Share of Central Nervous System (CNS) Stimulant Drugs The market for CNS stimulant drugs is experiencing growth through an expanding application in the adult population. Beyond addressing ADHD in children, there is an increasing recognition of ADHD persisting into adulthood. As a result, adults are seeking medical intervention, leading to a broader consumer base for CNS stimulant medications. According to a study published in the Journal of Clinical Psychiatry, the prevalence of ADHD in adults is estimated to be around 2.8%, reinforcing the notion

2. that adults represent a substantial and underexplored market segment for CNS stimulant drugs. Some of the major growth factors and challenges that are associated with the growth of the global central nervous system (CNS) stimulant drugs market are: Growth Drivers: • Increasing Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) • Growing Mental Health Awareness and Diagnosis Rates Challenges: Stringent regulatory scrutiny and evolving prescription restrictions pose challenges for the CNS stimulant drugs market. Regulatory authorities closely monitor the prescription and distribution of stimulant medications due to their potential for abuse. This increased scrutiny may lead to stricter regulations, making it challenging for healthcare professionals to prescribe these drugs, even in cases where they are medically necessary. The methylphenidate segment is to garner a highest revenue by the end of 2036 by growing at a significant CAGR over the forecast period. The off- label use of methylphenidate for cognitive enhancement purposes is a notable driver for the segment. While not officially endorsed for this purpose, individuals seeking improved focus and cognitive performance may use methylphenidate off-label. The demand for cognitive enhancers in academic and professional settings contributes to the sustained interest in methylphenidate. A study reported that approximately 20% of university students in the United States had used prescription stimulants, including methylphenidate, for non-medical purposes such as cognitive

3. enhancement. This off-label use trend indicates a market demand beyond traditional therapeutic applications. Request for customization @ https://www.researchnester.com/customized-reports-5524 By region, the Europe central nervous system (CNS) stimulant drugs market is to generate a notable revenue by the end of 2036. The growing awareness of neurological disorders, including attention deficit hyperactivity disorder (ADHD) and narcolepsy, is a significant driver. Increased awareness leads to more individuals seeking medical attention and diagnosis, contributing to the demand for CNS stimulant drugs. The rising prevalence of ADHD, both in pediatric and adult populations, is a key driver for the European CNS stimulant drugs market. The continuous increase in ADHD diagnoses necessitates pharmacological interventions, including stimulant medications. This report also provides the existing competitive scenario of some of the key players of the global central nervous system (CNS) stimulant drugs market which includes company profiling of Shire Pharmaceuticals LLC, Novartis International AG, Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc,and others. Access our detailed report @ https://www.researchnester.com/reports/central-nervous- system-stimulant-drugs-market/5524 About Research Nester- Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and

4. investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919